CN111423512B - 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 - Google Patents

阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 Download PDF

Info

Publication number
CN111423512B
CN111423512B CN201910023522.6A CN201910023522A CN111423512B CN 111423512 B CN111423512 B CN 111423512B CN 201910023522 A CN201910023522 A CN 201910023522A CN 111423512 B CN111423512 B CN 111423512B
Authority
CN
China
Prior art keywords
fusion protein
seq
domain
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910023522.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN111423512A (zh
Inventor
胡品良
邹敬
洪伟东
何芸
白洁
宋凌云
杨文第
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Beyond Biotechnology Co ltd
Original Assignee
Beijing Beyond Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Beyond Biotechnology Co ltd filed Critical Beijing Beyond Biotechnology Co ltd
Priority to CN201910023522.6A priority Critical patent/CN111423512B/zh
Priority to EP20738951.1A priority patent/EP3909986A4/en
Priority to US17/421,874 priority patent/US20220106389A1/en
Priority to PCT/CN2020/071213 priority patent/WO2020143720A1/zh
Priority to JP2021538762A priority patent/JP2022517920A/ja
Publication of CN111423512A publication Critical patent/CN111423512A/zh
Application granted granted Critical
Publication of CN111423512B publication Critical patent/CN111423512B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201910023522.6A 2019-01-10 2019-01-10 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 Active CN111423512B (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201910023522.6A CN111423512B (zh) 2019-01-10 2019-01-10 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
EP20738951.1A EP3909986A4 (en) 2019-01-10 2020-01-09 A MULTITARGET FUSION PROTEIN FOR BLOCKING VASIC ENDOTHELIUM GROWTH AND ACTIVATING T CELLS AND A PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
US17/421,874 US20220106389A1 (en) 2019-01-10 2020-01-09 Multi-targeting fusion protein for blocking the growth of vascular endothelial cells and activating t cells and pharmaceutical composition comprising the same
PCT/CN2020/071213 WO2020143720A1 (zh) 2019-01-10 2020-01-09 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
JP2021538762A JP2022517920A (ja) 2019-01-10 2020-01-09 血管内皮細胞の増殖をブロックし、ｔ細胞を活性化する多標的融合タンパク質、およびそれを含有する医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910023522.6A CN111423512B (zh) 2019-01-10 2019-01-10 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物

Publications (2)

Publication Number Publication Date
CN111423512A CN111423512A (zh) 2020-07-17
CN111423512B true CN111423512B (zh) 2024-01-05

Family

ID=71521813

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910023522.6A Active CN111423512B (zh) 2019-01-10 2019-01-10 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物

Country Status (5)

Country Link
US (1) US20220106389A1 (https=)
EP (1) EP3909986A4 (https=)
JP (1) JP2022517920A (https=)
CN (1) CN111423512B (https=)
WO (1) WO2020143720A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283522B2 (en) 2018-12-03 2025-03-01 Agensys Inc Pharmaceutical compositions containing anti-191P4D12 antibody drug conjugates and methods of using them
KR20220107257A (ko) * 2020-03-20 2022-08-02 레메젠 코, 리미티드 이중특이성 융합 단백질 및 그의 응용
WO2021238904A1 (zh) * 2020-05-25 2021-12-02 北京比洋生物技术有限公司 Fc-CD80融合蛋白和其缀合物以及它们的用途
CN116209466A (zh) * 2020-08-27 2023-06-02 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗鼻咽癌中的用途
CN113480614B (zh) * 2021-08-13 2023-01-10 中国人民解放军总医院 一类靶向pd-l1的超高亲和力小蛋白及用途
JP2025508267A (ja) * 2022-03-04 2025-03-21 パノロス バイオサイエンス インコーポレイテッド ＶＥＧＦ－Ｇｒａｂ及びＰＤ－１又はＰＤ－Ｌ１拮抗剤を含む併用投与用組成物
IL318220A (en) * 2022-07-25 2025-03-01 Agensys Inc Methods for treating patients with locally advanced or metastatic urinary tract cancer with antibody drug conjugates (ADCs) that bind 191P4D12 proteins in combination with pembrolizumab
TW202413427A (zh) * 2022-08-09 2024-04-01 大陸商上海濟煜醫藥科技有限公司 一種靶向ｐｄ－１和ｖｅｇｆ的抗體及其應用
JP2025534252A (ja) * 2022-09-14 2025-10-15 尋済生物科技（北京）有限公司 抗ｖｅｇｆａ抗体またはその抗原結合フラグメント、およびその使用
CN116102624B (zh) * 2023-03-07 2025-10-03 南京中医药大学 一种具有抑制血管生成作用的线性多肽及其环肽

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103167879A (zh) * 2010-07-09 2013-06-19 Abbvie公司 双重可变结构域免疫球蛋白及其用途
CN103502464A (zh) * 2010-12-02 2014-01-08 神经技术美国有限公司 分泌抗血管生成抗体支架和可溶性受体的细胞系及其用途
CN104159926A (zh) * 2011-12-01 2014-11-19 普腾生技有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
WO2015112900A1 (en) * 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof
CN107922470A (zh) * 2015-08-07 2018-04-17 皮里斯制药有限公司 对lag‑3和pd‑1特异性的新型融合多肽
CN109069638A (zh) * 2016-03-24 2018-12-21 源晟生物制药股份有限公司 用于癌症治疗的三特异性抑制剂
CN109053895A (zh) * 2018-08-30 2018-12-21 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1916001T1 (sl) * 2002-03-04 2011-10-28 Imclone Llc Äśloveĺ ka protitelesa specifiäśna za kdr in njihova uporaba
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
BRPI0913366A8 (pt) * 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
EP2435477A1 (en) * 2009-05-28 2012-04-04 Glaxo Group Limited Antigen-binding proteins
PE20120622A1 (es) * 2009-06-17 2012-05-26 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos
CN104195173B (zh) 2014-09-02 2017-03-08 北京比洋生物技术有限公司 具有双表达盒的谷氨酰胺合成酶高效表达载体
AU2016350701B2 (en) * 2015-11-02 2021-08-19 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
CN109563124A (zh) * 2016-06-17 2019-04-02 豪夫迈·罗氏有限公司 多特异性抗体的纯化
EP3596114A2 (en) * 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
CN108623691B (zh) * 2017-03-17 2020-05-15 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用
AU2018250641B2 (en) * 2017-04-11 2025-03-13 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103167879A (zh) * 2010-07-09 2013-06-19 Abbvie公司 双重可变结构域免疫球蛋白及其用途
CN103502464A (zh) * 2010-12-02 2014-01-08 神经技术美国有限公司 分泌抗血管生成抗体支架和可溶性受体的细胞系及其用途
CN104159926A (zh) * 2011-12-01 2014-11-19 普腾生技有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
WO2015112900A1 (en) * 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof
CN107922470A (zh) * 2015-08-07 2018-04-17 皮里斯制药有限公司 对lag‑3和pd‑1特异性的新型融合多肽
CN109069638A (zh) * 2016-03-24 2018-12-21 源晟生物制药股份有限公司 用于癌症治疗的三特异性抑制剂
CN109053895A (zh) * 2018-08-30 2018-12-21 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途

Also Published As

Publication number Publication date
EP3909986A4 (en) 2022-10-26
WO2020143720A1 (zh) 2020-07-16
EP3909986A1 (en) 2021-11-17
US20220106389A1 (en) 2022-04-07
CN111423512A (zh) 2020-07-17
JP2022517920A (ja) 2022-03-11

Similar Documents

Publication Publication Date Title
CN111423512B (zh) 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
CN109721657B (zh) 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
WO2019062642A1 (zh) 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
AU2020255712B2 (en) Anti-PD-L1/VEGF bifunctional antibody and use thereof
JP7464525B2 (ja) 標的療法のためのチェックポイント遮断を組み合わせる二官能性タンパク質
US20230235011A1 (en) Fc-cd80 fusion protein and conjugates thereof and their uses
US11667704B2 (en) Anti-IL-17 antibody/TNFR ECD fusion protein and use thereof
WO2020056085A1 (en) Spd-1 variant - fc fusion proteins
CN118871474A (zh) 抗pd-l1和vegf双特异性抗体及其应用
JP2022109934A (ja) 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質
JP2024534795A (ja) 二重特異性抗体およびその使用
JP2021526013A (ja) 抗ヒトｌａｇ−３モノクローナル抗体とその応用
KR20250139273A (ko) 삼중특이적 융합 단백질 및 이의 용도
CN115246885A (zh) 一种双特异性抗体及其应用
TWI916327B (zh) 結合pd-1的抗體
CA3107524A1 (en) Humanized anti-human ctla4 monoclonal antibody and preparation method and application thereof
US20250144178A1 (en) Pharmaceutical composition for cancer treatment comprising fusion protein including il-12 and anti-fap antibody and anticancer agent
HK40081178A (en) Bispecific fusion protein
WO2025056056A1 (zh) 药物组合及用途
HK40123044B (zh) 药物组合及用途
HK40123044A (zh) 药物组合及用途
TW202317608A (zh) 雙特異性融合蛋白
HK40030254B (zh) 结合检查点阻碍物作为目标治疗的双功能性蛋白质
HK40030254A (en) Bifunctional proteins combining checkpoint blockade for targeted therapy
BR112020013854B1 (pt) Proteínas bifuncionais que combinam bloqueio de ponto de verificação para a terapia alvejada

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant